Page last updated: 2024-10-27

fluorouracil and Right Ventricular Dysfunction

fluorouracil has been researched along with Right Ventricular Dysfunction in 1 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Thirty-seven consecutive patients with newly diagnosed breast cancer who were planned to receive either AC protocol [cyclophosphamide (600 mg/m(2)) + adriamycin (60 mg/m(2))] or CAF protocol [cyclophosphamide (600 mg/m(2)) + adriamycin (60 mg/m(2)) + 5-fluorouracil (600 mg/m(2))] for six cures were enrolled between February 2009 and June 2010."3.77Assessment of right ventricular functions during cancer chemotherapy. ( Alsancak, Y; Benekli, M; Buyukberber, S; Coskun, U; Demirci, U; Tacoy, G; Tanindi, A; Yalcin, R, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tanindi, A1
Demirci, U1
Tacoy, G1
Buyukberber, S1
Alsancak, Y1
Coskun, U1
Yalcin, R1
Benekli, M1

Other Studies

1 other study available for fluorouracil and Right Ventricular Dysfunction

ArticleYear
Assessment of right ventricular functions during cancer chemotherapy.
    European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2011, Volume: 12, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic

2011